A Goldman Sachs veteran says this platform would have funded faster as a rectal drug. Merck disagreed. Here's what took so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results